Histogenics (HSGX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS

Histogenics (NASDAQ:HSGX) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.05), MarketWatch Earnings reports.

Shares of Histogenics stock traded down $0.03 on Friday, hitting $0.51. 1,795,036 shares of the company’s stock traded hands, compared to its average volume of 8,070,151. Histogenics has a one year low of $0.50 and a one year high of $3.35. The firm has a market cap of $15.64 million, a price-to-earnings ratio of -0.52 and a beta of 1.02.

Several brokerages have recently weighed in on HSGX. HC Wainwright set a $1.00 price target on Histogenics and gave the company a “buy” rating in a research note on Friday. Brookline Cap M reissued a “buy” rating on shares of Histogenics in a research note on Wednesday, August 1st. Zacks Investment Research cut Histogenics from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Needham & Company LLC increased their price target on Histogenics to $5.00 and gave the company a “buy” rating in a research note on Thursday, September 6th. Finally, BTIG Research cut Histogenics from a “buy” rating to a “neutral” rating and set a $3.50 price target for the company. in a research note on Wednesday, September 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the stock. Histogenics has an average rating of “Hold” and an average price target of $3.25.

Institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its position in shares of Histogenics by 72.0% during the 2nd quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 22,927 shares in the last quarter. DRW Securities LLC bought a new stake in shares of Histogenics during the 2nd quarter valued at about $242,000. JPMorgan Chase & Co. bought a new stake in shares of Histogenics during the 1st quarter valued at about $320,000. Finally, Renaissance Technologies LLC boosted its position in shares of Histogenics by 6.1% during the 2nd quarter. Renaissance Technologies LLC now owns 384,329 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 22,133 shares in the last quarter. Institutional investors own 45.88% of the company’s stock.

WARNING: “Histogenics (HSGX) Posts Quarterly Earnings Results, Misses Expectations By $0.05 EPS” was first reported by Stock Observer and is the sole property of of Stock Observer. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.thestockobserver.com/2018/11/10/histogenics-hsgx-posts-quarterly-earnings-results-misses-expectations-by-0-05-eps.html.

About Histogenics

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Featured Article: Why do companies issue stock splits?

Earnings History for Histogenics (NASDAQ:HSGX)

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply